Adjuvant Carboplatin, Triple-Negative Breast Cancer, Phase 3 Randomized Trial
Effect of Adjuvant Carboplatin Intensified Chemotherapy versus Standard Chemotherapy on Survival in Women with High-Risk Early-Stage Triple-Negative Breast Cancer (CITRINE)
Randomized, open-label, phase 3 trial
808
Patients were randomized in a 1:1 ratio into either the carboplatin group (four cycles of two-week epirubicin and cyclophosphamide followed by four cycles of weekly paclitaxel combined with carboplatin) or the control group (four cycles of three-week or two-week epirubicin and cyclophosphamide followed by four cycles of weekly paclitaxel)
Disease-free survival (DFS) in the intention-to-treat population
The addition of carboplatin to adjuvant anthracycline/taxane-based chemotherapy significantly improves survival outcomes with manageable toxicity in patients with high-risk early-stage TNBC
